Emergent BioSolutions Inc. — Form 8-K
Filed September 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
BARDA (U.S. Department of HHS) awarded Emergent BioSolutions a contract modification valued at approximately $24 million to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness. The modification relates to contract HHSO100201600030C. CYFENDUS was FDA-approved in July 2023 for post-exposure prophylaxis in adults aged 18–65 when combined with antibacterial drugs. This award supplements Emergent's earlier 2026 delivery order valued up to $21.5 million for BioThrax® to the U.S. Department of War.
Why this rating
Contract worth ~$24M is ~7% of company's $342.7M market cap—material revenue but not transformational. Extends government relationship on approved product.
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.